Mission Bio's Single-Cell Platform Advances Biomarker Analysis for Incyte's MPN Therapy at ASH 2025
Key Insights
Mission Bio (search)'s Tapestri Platform supported exploratory biomarker analysis for Incyte's INCA033989 clinical trial targeting myeloproliferative neoplasms (search), with data presented at ASH 2025.
The single-cell multi-omics technology enabled detailed profiling of clonal evolution, treatment response, and resistance mechanisms in MPN patients.
INCA033989 is an investigational monoclonal antibody targeting mutant calreticulin (search), a key driver in MPN pathogenesis caused by genetic mutations in blood-forming stem cells.
Mission Bio (search) announced that its Tapestri Platform and custom assay development supported initial exploratory biomarker analysis data for Incyte's INCA033989 clinical trial, presented at the ASH 2025 conference in Orlando, Florida. The collaboration demonstrates the platform's ability to accelerate understanding of myeloproliferative neoplasms (search) (MPNs (search)) disease biology at the single-cell level.
Single-Cell Technology Enhances MPN Understanding
The Tapestri Platform enabled single-cell DNA and protein profiling to better understand clonal evolution, treatment response, and resistance mechanisms in MPN patients. The data presented at ASH 2025 illustrate how Tapestri's single-cell data was leveraged to understand disease persistence and clonal expansion in MPNs (search), subsequently providing deeper insights into clonal evolution, disease progression, and treatment response.
Myeloproliferative neoplasms (search) are a type of blood cancer (search) caused by genetic mutations in blood-forming stem cells. These mutations—found in the JAK2 (search), TPO-R (search), or CALR (search) genes—lead to uncontrolled growth of certain blood cells. INCA033989, an investigational monoclonal antibody, targets mutant calreticulin (search) (CALR), a key driver in MPN pathogenesis.
Platform Capabilities and Clinical Applications
The Tapestri Platform enables high-resolution detection of co-occurring mutations and cell surface protein expression, providing a more comprehensive picture of tumor heterogeneity and immune interactions in MPNs (search). By incorporating Mission Bio (search)'s single-cell technology, Incyte was able to better characterize clonal diversity, track resistance mechanisms, and refine patient stratification strategies to help advance the development of precision therapies for MPNs.
"Our collaboration with Incyte highlights the role of single-cell multi-omics as an advanced clinical biomarker tool and the potential power of single-cell analysis in supporting targeted therapy development in the clinic," said Brian Kim, CEO at Mission Bio (search). "By unraveling the complexity of MPNs (search) at the single-cell level, we can enhance complex biomarker analysis for targeted therapies in this space."
Technology Advantages in Precision Medicine
Unlike traditional methods such as bulk sequencing, the Tapestri Platform provides a level of precision that opens the door for more tailored and effective treatment strategies. The platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies.
Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. The platform continues to set the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.